Search

The latest research news from Retina UK.

• News
• Retinitis pigmentosa

This is the final edition of Look Forward this year and what a year it has been! We’ve had some very positive feedback about our Conferences and the Big Give Christmas Challenge is back - a great opportunity to double your donation at no extra cost to you! We’ve included a handy ‘What’s on’ article which outlines some of our plans for 2026. We would like to take this opportunity to wish all of our readers a very Merry Christmas and a happy and fulfilling New Year.

• Look Forward
• Audio
• Written

During RP awareness month, Paul Bacon has shared how his diagnosis has impacted his life and shared messages about how non visually impaired people can support those living with inherited sight loss. To learn more about inherited sight loss please take the time to read Paul's story.

• Story
• Retinitis pigmentosa

Our monthly e-Newsletter featuring the latest updates from Retina UK.

• e-Newsletter
• Audio
• Written

It has recently been announced that Meira-GTx, who originally developed bota-vec and collaborated with J&J during its early clinical trials, have entered into an asset purchase agreement with J&J to acquire bota-vec and progress the program towards global regulatory filings for approval.

• News
• Retinitis pigmentosa

Our community are the reason we are able to continue supporting those with inherited sight-loss conditions through research and practical support.

Retina UK is a charity supporting people affected by inherited sight loss and investing in medical research to help make their challenges a thing of the past.

Many inherited sight loss conditions occur when cells in the retina, which is the light-sensitive region at the back of the eye, deteriorate in an unpredictable way. These conditions are often referred to as inherited retinal dystrophies.

Stem cells are a special type of cell, which under the right conditions can be encouraged to grow into any other type of cell in the body, including retinal cells (rods, cones and retinal pigment epithelial cells).

When we talk about gene therapy we are usually referring to use of a harmless virus, called a vector, to deliver a normal copy of a defective gene into the cells of the eye.